### Anti-rabies immunoglobulin

**Indication**
Rabies

**ICD11 code:** 1C82

**Medicine type**
Biological agent

**List type**
Core

**Additional notes**
All human plasma-derived medicines should comply with the WHO requirements

**Formulations**
- Parenteral > General injections > IM: 150 IU per mL in vial
- Parenteral > Locoregional injections > Other: 150 IU per mL in vial

**EML status history**
- First added in 1991 ([TRS 825](#))
- Changed in 2007 ([TRS 950](#))
- Changed in 2013 ([TRS 985](#))
- Changed in 2015 ([TRS 994](#))

**Sex**
All

**Age**
Also recommended for children

**Therapeutic alternatives**
The recommendation is for this specific medicine

**Patent information**
Read more about patents.

**Wikipedia**
[Anti-rabies immunoglobulin](#)

**DrugBank**
[Anti-rabies immunoglobulin (Human rabies virus immune globulin)](#)

### Summary of evidence and Expert Committee recommendations

The Expert Committee recommended that immunoglobulins of human origin currently listed in Section 19.2 Sera and immunoglobulins, should be transferred to Section 11.2.1 Human immunoglobulins.